Perspectivas del mercado y visión del analista:
La creciente incidencia del cáncer de ovario impulsa el crecimiento del mercado de medicamentos contra el cáncer de ovario. Sin embargo, las retiradas de productos debido a efectos adversos impiden el crecimiento del mercado.
Impulsores de crecimiento:
La creciente incidencia de cáncer de ovario impulsa la demanda de opciones terapéuticas
El cáncer de ovario es el séptimo más frecuente cáncer más común entre las mujeres y el tercer cáncer ginecológico más común, después del cáncer de cuello uterino y el cáncer de endometrio (uterino), respectivamente. Según el informe de la Coalición Mundial contra el Cáncer de Ovario, a 324.000 mujeres se les diagnostica cáncer de ovario y 207.000 mujeres mueren a causa de la enfermedad cada año. Además, a la mayoría de las pacientes con cáncer de ovario se les diagnostica una afección en estadio avanzado (localmente avanzada o metastásica), ya que no existe un programa de detección de salud pública disponible para la detección temprana del cáncer de ovario. Por lo tanto, la creciente incidencia del cáncer de ovario impulsa la demanda de opciones terapéuticas eficaces. La terapia de primera línea con una combinación de cirugía citorreductora y quimioterapia basada en platino es la atención estándar para mujeres con diagnóstico reciente de cáncer de ovario avanzado. Además, las opciones terapéuticas como los inhibidores de PARP aprobados, olaparib, rucaparib y niraparib son opciones innovadoras para el tratamiento del cáncer de ovario recién diagnosticado. El uso de inhibidores de PARP en el tratamiento del cáncer de ovario avanzado también se ha convertido en una opción terapéutica eficaz para mejorar los resultados clínicos. Estos inhibidores proporcionan eficacia a largo plazo y supervivencia libre de progresión (SSP) en los casos recién diagnosticados, luego de una respuesta completa (RC) a la primera, segunda y tercera quimioterapia basada en platino.
Perspectivas estratégicas< br>
Segmentación y alcance del informe:
El análisis del mercado de medicamentos contra el cáncer de ovario se ha llevado a cabo considerando los siguientes segmentos: tipo, clase de medicamento y canal de distribución.
Análisis segmentario:
Por tipo, el mercado se segmenta en cáncer de ovario epitelial, cáncer de ovario de células germinales y tumores estromales. El segmento del cáncer de ovario epitelial tuvo la mayor cuota de mercado de medicamentos contra el cáncer de ovario en 2022; Se prevé que el mismo segmento registre la CAGR más alta del 8,2% durante el período previsto. Según el informe de Cancer Research UK, el cáncer de ovario epitelial es el tipo más común de cáncer de ovario. Por ejemplo, casi 90 de cada 100 tumores de ovario (90%) son tumores epiteliales. Las pacientes con cáncer de ovario agresivo en etapa avanzada tienen opciones de tratamiento limitadas disponibles en el mercado. En noviembre de 2022, la Administración de Alimentos y Medicamentos (FDA) anunció la aprobación de "mirvetuximab soravtansine-gynx", fabricado por Elahere ImmunoGen, Inc. para pacientes adultas que padecen cáncer de ovario epitelial. La dosis recomendada por el médico de este fármaco candidato para el tratamiento del cáncer de ovario epitelial es de 6 mg/kg, administrados una vez cada tres semanas como infusión intravenosa. En enero de 2024, la FDA anunció la aprobación de la designación por vía rápida (FTD) para "RC88", un conjugado anticuerpo-fármaco (ADC) dirigido a la mesotelina para el tratamiento de pacientes con cáncer de ovario epitelial recurrente. Por lo tanto, el creciente número de aprobaciones de medicamentos está impulsando el mercado de medicamentos contra el cáncer de ovario para el segmento del cáncer de ovario epitelial.
Mercado de medicamentos contra el cáncer de ovario, por tipo: 2022 y 2030
Tendencias del mercado de medicamentos contra el cáncer de ovario
Terapia con medicamentos combinados
Varios institutos de investigación médica están desarrollando nuevos medicamentos combinados para tratar el cáncer de ovario. En septiembre de 2023, investigadores del Royal Marsden anunciaron una nueva terapia de combinación de medicamentos que resulta eficaz en pacientes que viven con cáncer de ovario avanzado. Los investigadores probaron la terapia combinada de medicamentos para determinar su efecto sobre el cáncer de ovario seroso de bajo grado (LGSOC), una forma rara de cáncer de ovario con una tasa de respuesta deficiente a los tratamientos. El ensayo clínico RAMP-201 se llevó a cabo combinando el fármaco avutometinib con defactinib para investigar su efecto terapéutico sinérgico en pacientes que padecen LGSOC. Los resultados provisionales del ensayo clínico revelan que el 45% de los pacientes tratados con la combinación de fármacos vieron sus tumores reducirse significativamente. Estos resultados clínicos satisfactorios con la terapia combinada son casi dos veces más efectivos en comparación con trametinib, un fármaco de terapia dirigida disponible en Inglaterra que tiene una tasa de respuesta de sólo el 26%. En enero de 2024, la FDA anunció la aprobación del fármaco combinado SH-105 para el tratamiento de pacientes con cáncer de mama y de ovario. Por lo tanto, las terapias combinadas de medicamentos están surgiendo como nuevas tendencias que probablemente impulsen el crecimiento del mercado de medicamentos contra el cáncer de ovario en los próximos años.
Análisis regional:
El alcance del informe sobre el mercado de medicamentos contra el cáncer de ovario implica América del Norte, Europa, Asia Pacífico, América Central y del Sur, y Oriente Medio y África. En 2022, América del Norte tenía la mayor cuota de mercado de medicamentos contra el cáncer de ovario. El crecimiento del mercado en esta región está impulsado por el creciente número de lanzamientos de productos por parte de las principales empresas y la presencia de actores clave del mercado. Estados Unidos es el mayor contribuyente al mercado de América del Norte. La creciente incidencia de cáncer de ovario entre las mujeres obliga a las empresas y a los organismos reguladores a desarrollar y aprobar, respectivamente, medicamentos innovadores en esta región. Además, el creciente número de organizaciones de investigación clínica (CRO) por contrato favorece el crecimiento del mercado de medicamentos contra el cáncer de ovario en América del Norte.
Desarrollos de la industria y oportunidades futuras:
Pronóstico del mercado de medicamentos contra el cáncer de ovario puede ayudar a las partes interesadas en este mercado a planificar sus estrategias de crecimiento. A continuación se enumeran algunos desarrollos estratégicos de los principales actores que operan en el mercado:
•En noviembre de 2022, ImmunoGen obtuvo la aprobación de la FDA para ELAHERE (mirvetuximab soravtansine-gynx) para el tratamiento de pacientes adultos resistentes al platino. Cáncer de ovario epitelial resistente. ELAHERE está aprobado específicamente para pacientes con cáncer de ovario FRα positivo resistente al platino, que es una afección desafiante debido a la disponibilidad de opciones de tratamiento limitadas y los malos resultados clínicos de las terapias existentes. Panorama competitivo y empresas clave:
Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris y Luye Pharma se encuentran entre las empresas destacadas perfiladas en el informe del mercado de medicamentos contra el cáncer de ovario. Estas empresas se centran en desarrollar nuevas tecnologías, actualizar productos existentes y ampliar su presencia geográfica para satisfacer la creciente demanda de los consumidores en todo el mundo.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2022.
Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.
The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.
The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2022.
The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2022.
Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.
The CAGR value of the ovarian cancer drugs market during the forecasted period of 2022-2030 is 7.7%.
The List of Companies - Ovarian Cancer Drugs Market
- Elli Lilly
- AstraZeneca
- GSK
- Zielab
- ImmunoGen
- GeneTech (Roche)
- Vivesto
- Allarity Therapeutics, Inc.
- Aeterna Zentaris
- Luye Pharma
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)